

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Applicant:

Avi ORR-URTREGER et al

Serial No.: 10/516,303

Filed: 10-Dec-2004

For: METHOD OF DETECTING AND TREATING
PROSTATE CANCER

Examiner: HALVORSON, MARK

Group Art Unit: 1642

Attorney
Docket: 28906

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan
Registration No. 40,338

Dated: November 12, 2006



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/516,303
				Filing Date		December 10, 2004
				First Named Inventor		Avi ORR-URTREGER et al
				Art Unit		1642
				Examiner Name		HALVORSON, MARK
Sheet	1	of	7	Attorney Docket Number		28906

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-4,476,301	10-09-1984	Imbach et al.	
	2	US-4,656,127	04-07-1987	Mundy	
	3	US-4,666,828	05-19-1987	Gusella	
	4	US-4,683,202	07-28-1987	Mullis	
	5	US-4,801,531	01-31-1989	Frossard	
	6	US-4,816,567	03-28-1989	Cabilliy et al.	
	7	US-4,946,778	08-07-1990	Ladner et al.	
	8	US-5,011,771	04-30-1991	Bellet et al.	
	9	US-5,013,830	05-07-1991	Ohtsuka et al.	
	10	US-5,023,243	06-11-1991	Tullis	
	11	US-5,034,506	07-23-1991	Summerton et al.	
	12	US-5,149,797	09-22-1992	Pederson et al.	
	13	US-5,166,315	11-24-1992	Summerton et al.	
	14	US-5,177,196	01-05-1993	Meyer, Jr. et al.	
	15	US-5,185,444	02-09-1993	Summerton et al.	
	16	US-5,188,897	02-23-1993	Suhadolnik et al.	
	17	US-5,192,659	03-09-1993	Simons	
	18	US-5,214,134	05-25-1993	Weis et al.	
	19	US-5,216,141	06-01-1993	Benner	
	20	US-5,220,007	01-15-1993	Pederson et al.	
	21	US-5,235,033	08-10-1993	Summerton et al.	
	22	US-5,256,775	10-26-1993	Froehler	
	23	US-5,264,423	01-23-1993	Cohen et al.	
	24	US-5,264,562	11-23-1993	Matteucci et al.	
	25	US-5,264,564	11-23-1993	Matteucci et al.	
	26	US-5,272,057	12-21-1993	Smulson et al.	
	27	US-5,276,019	01-04-1994	Cohen et al.	
	28	US-5,278,302	01-11-1994	Caruthers et al.	
	29	US-5,286,717	02-15-1994	Cohen et al.	
	30	US-5,321,131	06-14-1994	Agrawal et al.	
	31	US-5,366,878	11-22-1994	Pederson et al.	
	32	US-5,399,676	03-21-1995	Froehler	
	33	US-5,403,711	04-04-1995	Walder et al.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/516,303
				Filing Date	December 10, 2004
				First Named Inventor	Avi ORR-URTREGER et al
				Art Unit	1642
				Examiner Name	HALVORSON, MARK
Sheet	2	of	7	Attorney Docket Number	28906
	34	US-5,405,938	04-11-1995	Summerton et al.	
	35	US-5,405,939	04-11-1995	Suhadolnik et al.	
	36	US-5,434,257	07-18-1995	Matteucci et al.	
	37	US-5,453,496	09-26-1995	Caruthers et al.	
	38	US-5,455,233	10-03-1995	Spielvogel et al.	
	39	US-5,466,677	11-14-1995	Baxter et al.	
	40	US-5,470,967	11-28-1995	Huie et al.	
	41	US-5,476,925	12-19-1995	Letsinger et al.	
	42	US-5,489,677	02-06-1996	Sanghvi et al.	
	43	US-5,491,133	02-13-1996	Walder et al.	
	44	US-5,519,126	05-21-1996	Hecht	
	45	US-5,536,821	07-16-1996	Agrawal et al.	
	46	US-5,539,082	07-23-1996	Nielsen et al.	
	47	US-5,541,306	07-30-1996	Agrawal et al.	
	48	US-5,541,307	07-30-1996	Cook et al.	
	49	US-5,545,806	08-13-1996	Lonberg et al.	
	50	US-5,545,807	08-13-1996	Surani et al.	
	51	US-5,550,111	08-27-1996	Suhadolnik et al.	
	52	US-5,561,225	10-01-1996	Maddry et al.	
	53	US-5,563,253	10-08-1996	Agrawal et al.	
	54	US-5,565,350	10-15-1996	Kmiec et al.	
	55	US-5,569,825	10-29-1996	Lonberg et al.	
	56	US-5,571,799	11-05-1996	Tkachuk et al.	
	57	US-5,587,361	06-24-1996	Cook et al.	
	58	US-5,589,136	12-31-1996	Northrup et al.	
	59	US-5,596,086	01-21-1997	Matteucci et al.	
	60	US-5,602,240	02-01-1997	De Mesmacker et al.	
	61	US-5,608,046	03-04-1997	Cook et al.	
	62	US-5,610,289	03-11-1997	Cook et al.	
	63	US-5,618,704	04-08-1997	Sanghvi et al	
	64	US-5,623,065	04-22-1997	Cook	
	65	US-5,625,050	04-29-1997	Beaton et al.	
	66	US-5,625,126	04-29-1997	Lonberg et al.	
	67	US-5,633,360	05-27-1997	Bischofberger et al.	
	68	US-5,633,425	05-27-1997	Lonberg et al.	
	69	US-5,652,355	07-29-1997	Metelev et al.	
	70	US-5,652,356	07-29-1997	Agrawal	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/516,303	
				Filing Date	December 10, 2004	
				First Named Inventor	Avi ORR-URTREGER et al	
				Art Unit	1642	
				Examiner Name	HALVORSON, MARK	
Sheet	3	of	7	Attorney Docket Number	28906	
	71	US-5,661,016	08-26-1997	Lonberg et al.		
	72	US-5,663,312	09-02-1977	Chaturvedula		
	73	US-5,677,437	10-14-1977	Teng et al.		
	74	US-5,677,439	10-14-1997	Weis et al.		
	75	US-5,700,922	12-23-1997	Cook		
	76	US-5,714,331	02-03-1998	Buchardt et al.		
	77	US-5,719,262	02-17-1998	Buchardt et al.		
	78	US-6,265,632	07-24-2001	Yayon et al.		
	79	US-6,303,374	10-16-2001	Zhang et al.		
	80	US-6,326,174	12-04-2001	Joyce et al.		
	81	US-6,331,396	12-18-2001	Silverman et al.		
	82	US-2002/0108142	08-02-2002	Kapranov et al.		
	83	US-2002/0086356	07-04-2002	Tuschl et al.		
	84	US-5,623,070	04-22-1997	Cook et al.		
	85	US-3,687,808	08-29-1972	Merigan, Jr. et al.		
	86	US-4,036,945	07-19-1977	Haber		
	87	US-4,331,647	05-25-1982	Goldenberg		
	88	US-4,469,863	09-04-1984	Ts'o et al.		
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	89	PCT WO 92/15712	09-17-1992	Goellet et al		
	90	PCT WO 03/000112	01-3-2003	Carpten et al.		
Examiner Signature				Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known				
				Application Number	10/516,303			
				Filing Date	December 10, 2004			
				First Named Inventor	Avi ORR-URTREGER et al			
				Group Art Unit	1642			
				Examiner Name	HALVORSON, MARK			
Sheet	4	Of	7	Attorney Docket Number	28906			
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²			
	91	Fingl et al. "Goodman & Gilman's: The Pharmacological Basis of Therapeutics", McGraw-Hill Professional, Chap.1, P.1, 2001.						
	92	Marks et al. By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", Biotechnology 10: 779-783, 1992.						
	93	Brummelkamp et al. "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells", Science, 296: 550-553, 2002.						
	94	Miyagishi et al. "U6 Promoter-Driven siRNAs With Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells", Nature Biotechnology, 19: 497-500, 2002;						
	95	Nyren et al. "Solid Phase DNA Minisequencing by an Enzymatic Luminometric Inorganic Pyrophosphate Detection Essay", Analytic Biochemistry, Vol.208, p.171-175, 1993.						
	96	Harlow et al. "Antibodies", A Laboratory Manuel, Cold Spring Harbor, P.141-155, 1988.						
	97	Rennert et al. "A Novel Founder Mutation in the RNASEL Gene, 471delAAAG, Is Associated With Prostate Cancer in Ashkenazi Jews", American Journal of Human Genetics, 71: 981-984, 2002.						
	98	Salehzada et al. "Polyclonal Antibodies Against Rnase L. Subcellular Localization of This Enzyme in Mouse Cells", The Journal of Biological Chemistry, 266(9): 5808-5813, 1991.						
	99	Rökmann et al. "Germline Alterations of the RNASEL Gene, A Candidate HPC1 Gene at 1q25, in Patients and Families With Prostate Cancer", Am. J. Hum. Genet., 70: 1299-1304, 2002.						
	100	Jones et al. "Replacing the Complementarity-Determining Regions on A Human Antibody With Those From A Mouse", Nature, 321: 522-525, 1986.						
	101	Mishell et al. "Selected Methods in Cellular Immunology", Freeman & Co., P. I-XIV, 1980.						
	102	Inbar et al. "Localization of Antibody-Combining Sites Within the Variable Portions of Heavy and Light Chains", Proc. Natl. Acad. Sci. USA, 69(9): 2659-2662, 1972.						
	103	Larrick et al. "PCR Amplification of Antibody Genes", Methods: A Companion to Methods in Enzymology, 2(2): 106-110, 1991.						
	104	Nickerson et al. "Automated DNA Diagnostics Using An ELISA-Based Oligonucleotide Ligation Assay", Proc. Natl. Acad. Sci. USA, 87: 8923-8927, 1990.						
	105	Bird et al. "Single-Chain Antigen-Binding Proteins", Science, 242(4877): 423-426, 1988.						
<table border="1" style="width: 100%;"> <tr> <td style="width: 20%;">Signature</td> <td style="width: 40%;"></td> <td style="width: 40%;">Considered</td> </tr> </table>						Signature		Considered
Signature		Considered						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/516,303
				Filing Date	December 10, 2004
				First Named Inventor	Avi ORR-URTREGER et al
				Group Art Unit	1642
				Examiner Name	HALVORSON, MARK
Sheet	5	Of	7	Attorney Docket Number	28906
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
	106	Breaker et al. "A DNA Enzyme With Mg ²⁺ -Dependent RNA Phosphoesterase Activity", Chemistry & Biology, 2: 655-660, 1995.			
	107	Khachigian "DNAzymes: Cutting A Path to A New Class of Therapeutics", Current Opinion in Molecular Therapeutics, 4(2): 119-121, 2002.			
	108	Pack et al. "Improved Bivalent Miniantibodies, With Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of Escherichia Coli", Bio/Technology, 11: 1271-1277, 1993.			
	109	Santoro et al. "A General Purpose RNA-Cleaving DNA Enzyme", Proc. Natl. Acad. Sci. USA, 94: 4262-4266, 1997.			
	110	Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications", Nature, 368: 856-859, 1994.			
	111	Neuberger "Generating High-Avidity Human Mabs in Mice", Nature Biotechnology, 14: 826, 1996.			
	112	Fishwild et al. "High-Avidity Human IgGκ Monoclonal Antibodies From A Novel Strain of Minilocus Transgenic Mice", Nature Biotechnology, 14: 845-851, 1996.			
	113	Morrison "Success in Specification", Nature, 368(6474): 812-813, 1994.			
	114	Boerner et al. "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes", The Journal of Immunology, 147(1): 86-95, 1991.			
	115	Lonberg et al. "Human Antibodies From Transgenic Mice", International Review in Immunology, 13: 65-93, 1995.			
	116	Hutvagner et al. "RNAi: Nature Abhors A Double-Strand", Current Opinion in Genetics & Development, 12: 225-232, 2002.			
	117	Berry et al. "Evidence for A Prostate Cancer-Susceptibility Locus on Chromosome 20", American Journal of Human Genetics, 67: 82-91, 2000.			
	118	Berthon et al. "Predisposing Gene for Early-Onset Prostate Cancer, Localized on Chromosome 1q42.2-43", American Journal of Human Genetics, 62(6): 1416-1424, 1998. Abstract.			
	119	Bisbal et al. "Cloning and Characterization of A Rnase L Inhibitor", The Journal of Biological Chemistry, 270(22): 13308-13317, 1995.			
	120	Carter et al. "Mendelian Inheritance of Familial Prostate Cancer", Proc. Natl. Acad. Sci. USA, 89: 3367-3371, 1992.			
	121	Englisch et al. "Chemically Modified Oligonucleotides as Probes and Inhibitors", Angewandte Chemie, International Edition, 30(6): 613-629, 1991. Abstract.			
Signature					
Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/516,303
				Filing Date	December 10, 2004
				First Named Inventor	Avi ORR-URTREGER et al
				Group Art Unit	1642
				Examiner Name	HALVORSON, MARK
Sheet	6	Of	7	Attorney Docket Number	28906
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
	122	Hacia et al. "Detection of Heterozygous Mutations in BRCA1 Using High Density Oligonucleotide Arrays and Two-Colour Fluorescence Analysis", Nature Genetics, 14(4): 441-447, 1996. Abstract.			
	123	Haff et al. "Multiplex Genotyping of PCR Products With Mass Tag-Labeled Primers", Nucleic Acids Research, 25(18): 3749-3750, 1997.			
	124	Harju et al. "Colorimetric Solid-Phase Minisequencing Assay Illustrated by Detection of Alpha 1-Antitrypsin Z Mutation", Clinical Chemistry, 39(11/Pt.1): 2282-2287, 1993. Abstract.			
	125	Hassel et al. "A Dominant Negative Mutant of 2-5A-Dependent Rnase Suppresses Antiproliferative and Antiviral Effects of Interferon", The EMBO Journal, 12(8): 3297-3304, 1993.			
	126	Hubert et al. "The Jewish Ashkenazi Founder Mutations in the BRCA1/BRCA2 Genes Are Not Found at An Increased Frequency in Ashkenazi Patients With Prostate Cancer", American Journal of Human Genetics, 65: 921-924, 1999.			
	127	Kozal et al. "Extensive Polymorphisms Observed in HIV-1 Clade B Protease Gene Using High-Density Oligonucleotide Arrays", Nature Medicine, 2(7): 753-759, 1996. Abstract.			
	128	Laken et al. "Familial Colorectal Cancer in Ashkenazim Due to A Hypermutable Tract in APC", Nature Genetics, 17(1): 79-83, 1997. Abstract.			
	129	Landegren et al. "Reading Bits of Genetic Information: Methods for Single-Nucleotide Polymorphism Analysis", Genome Research, 8: 769-776, 1998.			
	130	Lengyel "Tumor-Suppressor Genes: News About the Interferon Connection", Proc. Natl. Acad. Sci. USA, 90: 5893-5895, 1993.			
	131	Lichtenstein et al. "Environmental and Heritable Factors in the Causation of Cancer- Analyses of Cohorts of Twins From Sweden, Denmark, and Finland", New England Journal of Medicine, 343(2): 78-85, 2000. Abstract.			
	132	Livak et al. "A Microtiter Plate Assay for Determining Apolipoprotein E Genotype and Discovery of A Rare Allele", Human Mutation, 3(4): 379-385, 2005. Abstract.			
	133	Orita et al. "Detection of Polymorphisms of Human DNA by Gel Electrophoresis as Single-Strand Conformation Polymorphisms", Proc. Natl. Acad. Sci. USA, 86: 2766-2770, 1989.			
Signature		Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/516,303
				Filing Date	December 10, 2004
				First Named Inventor	Avi ORR-URTREGER et al
				Group Art Unit	1642
				Examiner Name	HALVORSON, MARK
Sheet	7	Of	7	Attorney Docket Number	28906
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
	134	Parker et al. "Cancer Statistics, 1996", CA - A Cancer Journal for Clinicians, 46(1): 5-27, 1996.			
	135	Pastinen et al. "Minisequencing: A Specific Tool for DNA Analysis and Diagnostics on Oligonucleotide Arrays", Genome Research, 7: 606-614, 1997.			
	136	Porter "The Hydrolysis of Rabbit γ -Globulin and Antibodies With Crystalline Papain", Biochemical Journal, 73: 119-126, 1959.			
	137	Shoemaker et al. "Quantitative Phenotypic Analysis of Yeast Deletion Mutants Using A Highly Parallel Molecular Bar-Coding Strategy", Nature Genetics, 14(4): 450-456, 1996. Abstract.			
	138	Silverman "Implications for Rnase L in Prostate Cancer Biology", Biochemistry, 42(7): 1805-1812, 2003. Abstract.			
	139	Smith et al. "Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by A Genome-Wide Search", Science, 274(5291): 1371-1374, 1996. Abstract.			
	140	Sosnowski et al. "Rapid Determination of Single Base Mismatch Mutations in DNA Hybrids by Direct Electric Field Control", Proc. Natl. Acad. Sci. USA, 94: 1119-1123, 1997.			
	141	Squire et al. "Localization of the Interferon-Induced, 2-5A-Dependent Rnase Gene (RNS4) to Human Chromosome 1q25", Genomics, 19(1): 174-175, 2001. Abstract.			
	142	Steinberg et al. "Family History and the Risk of Prostate Cancer", Prostate, 17(4): 337-347, 1990. Abstract.			
	143	Struewing et al. "The Carrier Frequency of the BRCA1 185delAG Mutation Is Approximately 1 Percent in Ashkenazi Jewish Individuals", Nature Genetics, 11(2): 198-200, 1995. Abstract.			
	144	Syvanen "Detection of Point Mutations in Human Genes by the Solid-Phase Minisequencing Method", Clinica Chimica Acta, 226(2): 225-236, 1994. Abstract.			
	145	Tavtigian et al. "A Candidate Prostate Cancer Susceptibility Gene at Chromosome 17p", Nature Genetics, 27: 172-180, 2001.			
	146	Tyagi et al. "Multicolor Molecular Beacons for Allele Discrimination", Nature Biotechnology, 16: 49-53, 1998. Abstract.			
	147	Verhoeven et al. "Reshaping Human Antibodies: Grafting An Antilysozyme Activity", Science, 239(4847): 1534-1536, 1988. Abstract.			
	148	Wang et al. "Role of HPC2/ELAC2 in Hereditary Prostate Cancer", Cancer Research, 61: 6494-6499, 2001.			
	149	Zhou et al. "Expression Cloning of 2-5A-Dependent Rnase: A Uniquely Regulated Mediator of Interferon Action", Cell, 72(5): 753-765, 1993. Abstract.			
	150	Hoogenboom et al. "By-Passing Immunisation. Human Antibodies From Synthetic Repertoires of Germline VH Gene Segments Rearranged In Vitro", Journal of Molecular Biology, 227(2): 381-388, 1992. Abstract.			

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount